← Pharming Group N.V. (PHAR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Pharming Group N.V. (PHAR)
Pharmaceutical Preparations · market cap $766M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Pharming Group N.V. (PHAR) is a Dutch specialty pharmaceutical company with 404 employees and a market cap of approximately $898M at ~$13.47/share. Its lead asset, leniolisib, is in Phase 3 development for PIDs linked to PI3K delta pathway dysregulation, with multiple near-term catalysts concentrated in late 2026. The pipeline also includes recombinant human C1 inhibitor programs across hereditary angioedema and genetic disorders, Ruconest in Phase 2 for coronavirus disease, and KL1333 in Phase 2 for primary mitochondrial disease.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ruconest | Phase 2 | Confirmed Coronavirus Disease |
| Leniolisib | Phase 3 | PIDs Linked to PI3K |
| i.v. recombinant human C1 inhibitor | Phase 3 | Genetic Disorders |
| recombinant human C1 inhibitor | Phase 3 | Hereditary Angioedema |
| rhC1INH | Phase 3 | Hereditary Angioedema |
| KL1333 | Phase 2 | Primary Mitochondrial Disease |
Price & technical context
3-month
-27.7%
6-month
-41.2%
12-month
-31.4%
52-wk range
$9.82–$21.18
vs 50-day MA
-11.6%
vs 200-day MA
-31.5%
Realized vol
66.2%
Max drawdown
-53.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PHAR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.